Collectively, these results demonstrate that the PD-L1 × CD47 siRNA conjugate exhibits strong tumor-targeting specificity and peripheral selectivity, preferentially accumulating in tumor-infiltrating Treg cells while sparing systemic immune cells and major organs. This evidence concerns the gene CD47 and neoplasm.